CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-09 | Morrison Briggs Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −28,273 | 0 | ||
| 2023-06-09 | Morrison Briggs Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −24,582 | 0 | ||
| 2023-05-09 | Morrison Briggs Director | Option exercise 10b5-1 | +52,855 | $6.38 | $337K | 70,691 |
| 2023-05-09 | Morrison Briggs Director | Sale 10b5-1 | −52,855 | $21.41 | $1.1M | 17,836 |
| 2023-05-09 | Morrison Briggs Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −52,855 | 0 | ||
| 2023-04-10 | Morrison Briggs Director | Option exercise 10b5-1 | +52,855 | $6.38 | $337K | 70,691 |
| 2023-04-10 | Morrison Briggs Director | Sale 10b5-1 | −52,855 | $19.53 | $1.0M | 17,836 |
| 2023-04-10 | Morrison Briggs Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −52,855 | 0 | ||
| 2023-04-10 | Gallagher Neil President, Head of R&D | Grant or award · Stock Options (Right to buy) | +250,000 | $19.35 | $4.8M | 250,000 |
| 2023-03-13 | Morrison Briggs President, Head of R&D | Option exercise | +52,854 | $6.38 | $337K | 70,690 |
| 2023-03-13 | Morrison Briggs President, Head of R&D | Sale | −52,854 | $22.53 | $1.2M | 17,836 |
| 2023-03-13 | Morrison Briggs President, Head of R&D | Option exercise · Stock Option (Right to Buy) | −52,854 | 0 | ||
| 2023-02-15 | Ordentlich Peter Chief Scientific Officer | Option exercise | +7,572 | $6.38 | $48K | 7,572 |
| 2023-02-15 | Ordentlich Peter Chief Scientific Officer | Sale | −7,572 | $25.84 | $196K | 0 |
| 2023-02-15 | Ordentlich Peter Chief Scientific Officer | Option exercise | +17,428 | $7.20 | $125K | 17,428 |
| 2023-02-15 | Ordentlich Peter Chief Scientific Officer | Sale | −17,428 | $25.84 | $450K | 0 |
| 2023-02-15 | Ordentlich Peter Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −17,428 | $25.84 | $450K | 0 |
| 2023-02-15 | Ordentlich Peter Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −7,572 | $25.84 | $196K | 0 |
| 2023-02-06 | Metzger Michael A Chief Executive Officer | Option exercise | +5,959 | $6.38 | $38K | 23,618 |
| 2023-02-06 | Metzger Michael A Chief Executive Officer | Sale | −5,959 | $27.64 | $165K | 17,659 |
Page 7 of 15 · 290 trades